Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPCXM18 for acute ischemic stroke (Phase II)
CTR20230311Phase 2Completed
- Sponsor
- KPC Pharmaceuticals
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ginsenotriol disuccinate sodium in ischemic stroke, sponsored by KPC Pharmaceuticals. Started Feb 2023; status: completed.
02
Drugs
ginsenotriol disuccinate sodium
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20230311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230311.